Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
3(38%)
Results Posted
33%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_3
1
13%
Ph not_applicable
1
13%
Ph phase_2
1
13%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(4)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Recruiting2
Active, not recruiting1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)

Trials by Status

completed338%
active_not_recruiting113%
not_yet_recruiting113%
recruiting225%
terminated113%

Recent Activity

3 active trials
Showing 5 of 8
completed

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

NCT02743910
active_not_recruitingphase_3

3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol

NCT05458622
completed

3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2

NCT05747651
recruiting

From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With MGLS and HSFP

NCT04174066
not_yet_recruiting

UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

NCT06895681
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02743910

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

Completed
NCT05458622Phase 3

3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol

Active Not Recruiting
NCT05747651

3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2

Completed
NCT04174066

From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With MGLS and HSFP

Recruiting
NCT06895681

UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

Not Yet Recruiting
NCT03959904Not Applicable

The Impact of Abdominal Wall Closure Technique on Incidence of Incisional Hernia in Kidney Transplantation

Recruiting
NCT00319735Phase 2

Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

Completed
NCT00632294

Retrospective Study of the Biomechanical Properties of Large Allografts

Terminated

All 8 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
8